Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Data just for cohorts 1-4 no?
What’s your strategy Thorno? If you don’t mind me asking
Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).
Doctors don’t hang around when cancer is concerned - you’re treated PDQ, you’re not sitting round waiting for months. AVCT have either started their Arm 2 or they are yet to find a single patient prepared to trial AVA6000 where their physician goes on the record stating “the safety data when compared with standard doxorubicin are highly encouraging”… imagine accompanied by discussion noting higher/stronger relative dose, administered more frequently (just 2 weeks!) without the side effects
personal view is that Arm 2 is underway
“ The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).”
And surely C7 must about be completed no? …. With some patients continuing to receive treatment at that level etc etc
Maybe they are just “getting on with it” - dosing up to C7 and they’ll tell the market when they’ve exceeded a Phase 1 dose level previously administered.
I mean, they have told us the plan to go to fortnightly dosing via RNS, they’ve told us they’re screening, it might have already started. It’s still phase 1. “We’ve administered another patient at C3 levels but now on the fortnightly regimen” - maybe they’ll let the market know when they exceed the C7 dose around July/August?
Well this is what I have been thinking, also still wondering whether it would be RNSable given they are still dosing at levels previously dosed. It’s nothing untied and untested.
Extreme point, let’s say we were dosing every 60 days and then they went to dosing every 59 days…. Would that be RNSable?
I can’t help but feel like we’ll get an RNS to say we’ve reached what we believe to be fortnightly MTD, and the mats equivalent of C5/C6/C7/C8…. And I k ow some vehemently disagree with that notion…. But they’re now trialling a tried and tested substance, slightly more frequently. They’ve been there and done that… and are still doing that
It may have been discussed previously so sorry if I have missed it - They were screening patients for Arm 2 middle of December, stated during the company presentation, how long should that take? I would have expected it to have commenced with 8 weeks of commencement of screening. And wasn’t the intention to conclude the Arm2 before Q3?
I have basically downed tools - ROFLMFAO at the whole LFT chat -earth to imbecile come in imbecile
Yes B2, it’s just unfortunate that only STS expresses high FAP…. Oh wait 😉
Dr Tap
Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
"These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION™ platform to avoid normal tissue effects while concentrating the toxin in the tumor microenvironment."
Everyone need to get the Vox markets app man - they land instantly
Nm
Yeah, that’s the existing standard of care, mate
Dox with a new delivery mechanism
New standard of care
Can’t help but feel the RNS will be issued at 11am or after the presentation
50% chance we get and RNS tomorrow
Mine were of a similar nature, plus additional detail of whether any earlier cohorts that successfully completed C4, found themselves taking C5 or even C6 levels of AVA6k following successful completion of the 3 cycles the respective regimen.
Q to the BB - Does it even have to demonstrate efficacy if it’s proven to be Dox at the tumour? and therefore just a safer version of Dox? Does this small (albeit prolonged/extended study provide sufficient evidence/confidence for fast track approval? 🤔
Has anybody posted any questions in advance of Wednesday? I posted one earlier, it was like 6 Q's in one (hope they don't notice!) but all along a similar theme with slight variations of a theme
Anything is possible - safety profile is exceptional, and in case it hasn’t clicked yet, this is a novel means of delivery for an existing treatment that is only activated where it is required.
Struggle to wonder why it couldn’t be fast tracked for approval if it is safe/inactive going in and effective/active when at the tumour target… it’s Dox but only when at the tumour. It’s anybody’s guess what new information Wednesday will bring but I for one am strapped in for the ride.
Cohort 7 completion has to be any day now also, I wouldn’t be surprised if that is also out this week too
Not many companies in the world have the technology that Avacta have - a lot are saying they want it…
LSE should probs also confiscate the doors - because on Wednesday afternoon they’ll be reduced to splinters
I only said - make it bloody tolerable!!!